Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis.
The impact of the fibroblast growth factor receptor 4 (FGFR4) Gly388Arg polymorphism on bladder cancer is unknown. We found no clear correlations between the FGFR4 genotype and risk of bladder cancer or pathological parameters. Neither the polymorphism nor TP53 mutation status was an independent predictor of prognosis, but they might act jointly on the disease-specific survival of patients.
Yang
Y C
YC
Department of Epidemiology, UCLA School of Public Health and Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA.
Lu
M L
ML
Rao
J Y
JY
Wallerand
H
H
Cai
L
L
Cao
W
W
Pantuck
A
A
Dalbagni
G
G
Reuter
V
V
Figlin
R A
RA
Belldegrun
A
A
Cordon-Cardo
C
C
Zhang
Z F
ZF
D000368:Aged; D004252:DNA Mutational Analysis; D005260:Female; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011379:Prognosis; D051499:Receptor, Fibroblast Growth Factor, Type 4 / Q000235:genetics*; D016019:Survival Analysis; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000235:genetics* / Q000401:mortality*
C496371:FGFR4 protein, human; D051499:Receptor, Fibroblast Growth Factor, Type 4